Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Impact of different diagnostic measures on drug class association with dementia progression risk: a longitudinal prospective cohort study

View ORCID ProfileDaman Kaur, Magda Bucholc, View ORCID ProfileDavid P. Finn, View ORCID ProfileStephen Todd, View ORCID ProfileKongFatt Wong-Lin, Paula L. McClean
doi: https://doi.org/10.1101/2021.08.03.21261570
Daman Kaur
aNorthern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, Clinical Translational Research and Innovation Centre (C-TRIC), Altnagelvin Hospital Site, Derry∼Londonderry BT47 6SB, Northern Ireland, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daman Kaur
  • For correspondence: kaur-d1@ulster.ac.uk
Magda Bucholc
bIntelligent Systems Research Centre, School of Computing, Engineering and Intelligent Systems, Ulster University, Northland Rd, Derry∼Londonderry BT48 7JL, Northern Ireland, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David P. Finn
cPharmacology and Therapeutics, School of Medicine, Galway Neuroscience Centre, Human Biology Building, National University of Ireland Galway, University Road, Galway H91 W5P7, Republic of Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David P. Finn
Stephen Todd
dAltnagelvin Area Hospital, Western Health and Social Care Trust, Derry∼Londonderry BT47 6SB, Northern Ireland, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephen Todd
KongFatt Wong-Lin
bIntelligent Systems Research Centre, School of Computing, Engineering and Intelligent Systems, Ulster University, Northland Rd, Derry∼Londonderry BT48 7JL, Northern Ireland, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for KongFatt Wong-Lin
Paula L. McClean
aNorthern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, Clinical Translational Research and Innovation Centre (C-TRIC), Altnagelvin Hospital Site, Derry∼Londonderry BT47 6SB, Northern Ireland, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Clinical Dementia Rating Sum of Boxes (CDRSOB) scale is known to be highly indicative of cognitive-functional status, but it is unclear whether it is consistent with clinical diagnosis in evaluating drug class associations with risk of progression to mild cognitive impairment (MCI) and dementia.

Methods We employed multivariable logistic regression on longitudinal NACC data, to identify drug classes associated with disease progression risk, using clinical diagnosis and CDRSOB as the outcome.

Results Anticoagulants, non-steroidal anti-inflammatory drugs, antihypertensives, antidepressants, and Parkinson’s medications were significantly associated with decreased progression to mild cognitive impairment (MCI)/dementia, and antipsychotics, antidiabetics, hypolipidemic drugs, and Alzheimer’s disease (AD) medications were significantly associated with increased progression risk. Associations were however dependant on the diagnostic measure used, e.g., levodopa was associated with reduced MCI-to-AD risk using CDRSOB as the outcome (OR:0.28, FDR p<0.002), but not with clinical diagnosis. Additionally, some associations appear to be gender specific; for instance, antiadrenergic agents had lower MCI-to-Dementia risk only for men (OR:0.67, FDR p<0.001) using CDRSOB.

Conclusions Overall, we demonstrate that choice of diagnostic measure can influence the magnitude and significance of risk or protection attributed to drug classes. A consensus must be reached within the research community with respect to the most accurate diagnostic outcome to identify risk and improve reproducibility.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This project was supported by the European Unions INTERREG VA Programme managed by the Special EU Programmes Body with additional support by the Northern Ireland Functional Brain Mapping Project Facility funded by invest Northern Ireland and the University of Ulster ARUK NI Pump Priming and Ulster University Research Challenge Fund and the Dr George Moore Endowment for Data Science at Ulster University

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

NA

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This work was supported by the European Union’s INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB (Centre for Personalised Medicine, IVA 5036)), with additional support by the Northern Ireland Functional Brain Mapping Project Facility (1303/101154803), funded by invest Northern Ireland and the University of Ulster (K.W.-L.), Alzheimer’s Research UK (ARUK) NI Pump Priming (M.B.,S.T.,K.W.-L.,P.L.M.), Ulster University Research Challenge Fund (M.B.,S.T.,K.W.-L.,M.B.), and the Dr George Moore Endowment for Data Science at Ulster University (M.B.).

  • Ph: +44 (0) 2871675675

  • Ph: +44 (0) 2871675320

  • Ph: +353-91-495586

  • Ph: +44 (0) 2871345171

  • Declarations of interest: none

  • Methods section updated to adjust for important confounders; Accordingly the Results section is updated; All figures updated; Supplemental files updated.

Data Availability

The processed data can be found in the results section in the manuscript and Supplementary Table. R codes for data preparation and analysis will be uploaded to GitHub in due course. Data source: NACC asks investigators to not share the data with individuals who are not collaborators on the project for which the data was requested. This is partially due to the fact that they have distinctions between commercial and noncommercial recipients in place due to the option for NACC participants to elect to decline sharing of their data with commercial entities. Additionally, NACC has a data use agreement in place to help prevent misuse of the data. Lastly, this is helpful in the tracking of proposals, publications and data requests. NACC data is available through request to any interested researcher regardless of commerciality. At the time of the request submission, investigators will be asked to provide details of the proposal and will need to submit a data use agreement. Requests can be submitted on the website (https://naccdata.org/requesting-data/submit-data-request).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 25, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Impact of different diagnostic measures on drug class association with dementia progression risk: a longitudinal prospective cohort study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Impact of different diagnostic measures on drug class association with dementia progression risk: a longitudinal prospective cohort study
Daman Kaur, Magda Bucholc, David P. Finn, Stephen Todd, KongFatt Wong-Lin, Paula L. McClean
medRxiv 2021.08.03.21261570; doi: https://doi.org/10.1101/2021.08.03.21261570
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Impact of different diagnostic measures on drug class association with dementia progression risk: a longitudinal prospective cohort study
Daman Kaur, Magda Bucholc, David P. Finn, Stephen Todd, KongFatt Wong-Lin, Paula L. McClean
medRxiv 2021.08.03.21261570; doi: https://doi.org/10.1101/2021.08.03.21261570

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1094)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9760)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2304)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1554)
  • Health Policy (734)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (502)
  • Infectious Diseases (except HIV/AIDS) (11637)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2140)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1173)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (266)
  • Psychiatry and Clinical Psychology (2176)
  • Public and Global Health (4649)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (456)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)